




>>Entry Name: Irinotecan, BAN, INN

Synonym(s): 4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate, 9Cl. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin. Camptetin. Campto. Camptosar. Topotecin. CPT 11



Molecular Formula: C₃₃H₃₈N₄O₆

Molecular Weight: 586.686

Accurate Mass: 586.279136

Percentage Composition: C 67.56%; H 6.53%; N 9.55%; O 16.36%

Source/Synthesis: Semisynthetic, synthesised from Camptothecin [CFK58-X](#)

Use/Importance: Topoisomerase I inhibitor. Antineoplastic agent

Development Status: Launched 1994 (Japan)

Calculated Log P Data: Log P 2.45 (uncertain value) (calc)

Other Data: Less toxic than Camptothecin [CFK58-X](#)

>>Variant: (*S*)-form

CAS Registry Number: 97682-44-5

Molecular Formula: C₃₃H₃₈N₄O₆

Molecular Weight: 586.686

Accurate Mass: 586.279136

Percentage Composition: C 67.56%; H 6.53%; N 9.55%; O 16.36%

Physical Description: Pale yellow powder

Melting Point: Mp 222-223°

>>Derivative: Hydrochloride

Synonym(s): Irinotecan hydrochloride, JAN, USAN

CAS Registry Number: 100286-90-6

Hazard & Toxicity: LD₅₀ (rat, orl) 867 mg/kg. LD₅₀ (rat, ivn) 83.6 mg/kg. Exp. reprod. and teratogenic effects. Mutagen

>>Derivative: Hydrochloride, trihydrate

CAS Registry Number: 136572-09-3

Physical Description: Pale yellow needles (H₂O)

Melting Point: Mp 256.5°

Optical Rotation: [α]_D²⁰ +67.7 (c, 1 in H₂O)

References:

- Kunimoto, T. *et al.*, *Cancer Res.*, 1987, **47**, 5944, (*pharmacol*)
Koike, K. *et al.*, *Gen. Pharmacol.*, 1989, **20**, 763, (*pharmacol*)
Kaneda, N. *et al.*, *Cancer Res.*, 1990, **50**, 1715, (*metab*)
Sawada, S. *et al.*, *Chem. Pharm. Bull.*, 1991, **39**, 1446, (*synth, trihydrate, pmr, uv, cmr, cryst struct, activity*)
Atsumi, R. *et al.*, *Xenobiotica*, 1991, **21**, 1159, (*metab*)
Aiyama, R. *et al.*, *Chem. Pharm. Bull.*, 1992, **40**, 2810, (*uv, cd, bibl*)
Burris, H.A. *et al.*, *Semin. Oncol.*, 1992, **19**, 663, (*use, rev*)
Rivory, L.P. *et al.*, *Cancer Res.*, 1994, **54**, 6330, (*metab, human*)
Curran, D.P. *et al.*, *Angew. Chem., Int. Ed.*, 1995, **34**, 2683, (*synth*)
Wiseman, L.R. *et al.*, *Drugs*, 1996, **52**, 606, (*rev*)
Boisseau, M. *et al.*, *Expert Opin. Invest. Drugs*, 1996, **5**, 613, (*rev*)
Henegar, K.E. *et al.*, *J.O.C.*, 1997, **62**, 6588-6597, (*synth*)
Robert, J. *et al.*, *Drugs of Today (Barcelona)*, 1998, **34**, 777-803, (*rev*)
Nitta, K. *et al.*, *Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th, 1985*, **1**, 28, (*synth, pharmacol*)